Kevin Hern | VP, IR |
David Ricks | Chairman, CEO & President |
Anat Ashkenazi | SVP & CFO |
Dr. Dan Skovronsky | SVP, Chief Scientific Officer & President, Lilly Research Labs |
Michael Mason | SVP & President, Lilly Diabetes |
Terence Flynn | Goldman Sachs |
Aaron Gal | Sanford C. Bernstein |
Timothy Anderson | Wolfe Research |
Christopher Schott | JPMorgan |
Umer Raffat | Evercore |
Andrew Baum | Citigroup |
Louise Chen | Cantor |
Geoff Meacham | Bank of America |
Carter Gould | Barclays |
Seamus Fernandez | Guggenheim |
Vamil Divan | Mizuho Securities |
Steve Scala | Cowen |
Matthew Harrison | Morgan Stanley |
Ladies and gentlemen, thank you for standing by, and welcome to Lilly’s Q2 Earnings Call. [Operator Instructions].
As a reminder, today's conference is being recorded. I would now like to turn the conference over to our host, Vice President of Investor Relations, Kevin Hern. Please go ahead.